Sugi Predict

Sugi Predict / Compounds / SCHEMBL4400837

SCHEMBL4400837

SCHEMBL4400837

CC(C)(C)OC(=O)N1CCCCC1CC=O

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PDE8B O95263 1/20 0.47
▸ KDM1A O60341 1/20 0.43
▸ ATM Q13315 2/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ EPHX1 P07099 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ PREP P48147 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ CHEK2 O96017 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11995153 1.00 PDE8B (0.47) PDE8BKDM1AATMHSD17B10HPGD
SCHEMBL11990570 1.00 PDE8B (0.47) PDE8BKDM1AATMHSD17B10HPGD
SCHEMBL28196934 0.95 HSD17B10 (0.46) PDE8BATMHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL1516388 0.95 HSD17B10 (0.46) PDE8BATMHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL115847 0.95 HSD17B10 (0.46) PDE8BATMHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL30566525 0.89 HSD17B10 (0.39) PDE8BATMHSD17B10HPGDSMN1; SMN2
SCHEMBL15594469 0.89 HSD17B10 (0.39) PDE8BATMHSD17B10HPGDSMN1; SMN2
SCHEMBL25867303 0.87 PDE8B (0.47) PDE8BKDM1AATMHSD17B10HPGD
SCHEMBL7203146 0.86 PDE8B (0.46) PDE8BKDM1AATMHSD17B10HPGD
SCHEMBL4712266 0.86 ATM (0.46) PDE8BKDM1AATMHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119677734-A Aromatic heterocyclic cyclohexane amino alkyl piperidine derivative, preparation method and application thereof 江苏恩华药业股份有限公司 2025-03-21 — — CN disclosed
CN-116507333-A Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use 上海睿跃生物科技有限公司 2023-07-28 — — CN disclosed
CN-116322700-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2023-06-23 — — CN disclosed
WO-2023034290-A1 NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION (US) 2023-03-09 — — WO disclosed
WO-2023283213-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION (US) 2023-01-12 — — WO disclosed
EP-3970723-A1 AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN Asana BioSciences, LLC (US) 2022-03-23 — — EP disclosed
EP-3363437-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS SOLUTIONS (US) 2021-07-28 — — EP disclosed
EP-3363437-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS SOLUTIONS (US) 2021-07-28 — — EP disclosed
CN-107540599-B Aminoindane compounds and their use to treat pain 阿萨纳生物科技有限责任公司 2021-06-04 — — CN disclosed
EP-3363437-A1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN Endo Pharmaceuticals Solutions Inc. (US) 2018-08-22 — — EP disclosed
CN-101252929-A G protein-coupled receptor agonists PROSIDION LTD (GB) 2008-08-27 — — CN disclosed
US-20040192673-A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists SMITHKLINE BEECHAM PLC (GB) 2004-09-30 — — US disclosed
EP-1435955-A2 N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SmithKline Beecham P.L.C. (GB) 2004-07-14 — — EP disclosed
WO-2002089800-A2 N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM P.L.C. (GB) 2002-11-14 — — WO disclosed
EP-0734379-B1 2-ARYLALKENYL-AZACYCLOALKANE DERIVATIVES AS SIGMA RECEPTOR LIGANDS, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF PARKE DAVIS (FR) 2001-03-07 — — EP disclosed
EP-0995436-A2 Ligands for sigma receptors and their therapeutical applications PARKE-DAVIS (FR) 2000-04-26 — — EP disclosed
US-6013656-A PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS; NERVOUSSYSTEM DISORDERS WARNER-LAMBERT COMPANY (US) 2000-01-11 — — US disclosed
US-5849760-A 2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors INSTITUT DE RECHERCHE JOUVEINAL (FR) 1998-12-15 — — US disclosed
EP-0734379-A1 NOVEL 2-ARYLALKENYL-AZACYCLOALKANE DERIVATIVES AS SIGMA RECEPTOR LIGANDS, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF INSTITUT DE RECHERCHE JOUVEINAL (I.R.J) (FR) 1996-10-02 — — EP disclosed
WO-1995015948-A1 NOVEL 2-ARYLALKENYL-AZACYCLOALKANE DERIVATIVES AS SIGMA RECEPTOR LIGANDS, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF INSTITUT DE RECHERCHE JOUVEINAL (FR) 1995-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192673-A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists HCRTR2, HCRTR1, NPY1R PDE8B 3067/4885KDM1A 1371/4885ATM 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.